The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
Generic semaglutide (the biosimilar version of Ozempic) is running out at pharmacies across Quebec due to recalls and surging demand. If you're currently on this medication or planning to start, here's what the shortage means for your treatment and what alternatives exist.
Singapore has approved Wegovy (semaglutide) as the first medication specifically indicated for MASH with liver fibrosis, a serious liver condition affecting millions globally. This expands the growing body of evidence that GLP-1 medications do far more than help with weight loss. Here is what patients and those considering GLP-1 therapy need to know.
Medicare's GLP-1 coverage program has reached 700,000 seniors, with Eli Lilly capturing roughly 70% of that market. This milestone signals a major shift in how older Americans access weight loss and diabetes medications, but navigating the coverage details still takes work.
On Jimmy Kimmel Live! in August 2026, Leslie Mann said her husband, director Judd Apatow, has gained about 15 pounds in four years on the highest dose of Ozempic because he likes to override the fullness it creates. His story is a clear example of how GLP-1 medications work and where their limits are.
On August 28, 2026, the FDA approved Mounjaro (tirzepatide) to lower the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes who are at high cardiovascular risk. The approval rests on SURPASS CVOT, which compared Mounjaro head to head with Trulicity. It does not extend to people with obesity who do not have diabetes.
Jelly Roll went from about 540 pounds to 265 and says a GLP-1 played almost no part. He tried one for two weeks early on, then stopped. His story is a useful reminder that there is more than one path to major weight loss, and that GLP-1 medications are a legitimate one.
China's drug regulator has formally accepted Novo Nordisk's application for oral semaglutide, the pill version of Wegovy. This milestone signals growing global demand for convenient GLP-1 options and could have ripple effects on access and pricing worldwide. Here's what patients need to know.
California's SB 1089, signed into law on September 28, 2026, started as a proposal to require GLP-1 coverage for public employees and was scaled back to a CalRx effort to lower GLP-1 prices. Here's what the law does, why Medi-Cal ended obesity coverage, and what you can do right now if cost is standing between you and treatment.
